^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Published date:
01/10/2022
Excerpt:
The addition of atezolizumab to enzalutamide in an open-label randomized trial….In planned biomarker analysis, longer progression-free survival was seen with atezolizumab in patients with high PD-L1 IC2/3, CD8 expression and established immune gene signatures. Exploratory analysis linked progression-free survival in the atezolizumab arm with immune genes such as CXCL9 and TAP1....Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer...
DOI:
https://doi.org/10.1038/s41591-021-01600-6
Trial ID:
